Deerfield Beach, FL -- (SBWIRE) -- 07/28/2015 -- Global Biosimulation Market 2015-2018

Global Biosimulation Market 2015-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, the APAC region, and the ROW; it also covers the Global Biosimulation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Global Biosimulation market to grow at a CAGR of 18.31 percent over the period 2013-2018.

One of the key factors contributing to this market growth is the reduction in drug discovery and development costs, owing to the deployment of biosimulation solutions. The Global Biosimulation market has also been witnessing increasing collaborations and partnerships. However, issues associated with the accuracy in prediction, could pose a challenge to the growth of this market.

The key vendors dominating this market space are Accelrys Inc., Certara L.P., Schrodinger Llc. and Simulation Plus Inc.

Request For Research Report Sample @ http://www.marketresearchstore.com/report/global-biosimulation-market-2014-2018-25721#requestSample

Other vendors mentioned in the report are Advanced Chemistry Development Inc., Archimedes Inc., Bayer Technology Services, Biomed Simulation Inc., Chemical Computing Group Inc., Compugen Ltd., Entelos Inc., Genedata AG, Immunetrix Inc., InhibOx Ltd., INOSIM Software GmbH, In Silico Biosciences Inc., Insilico Biotechnology AG, LeadInvent Technologies Pvt. Ltd., Leadscope Inc., Molecular Knowledge Systems Inc., Nimbus Discovery Llc, OpenEye Scientific Software Inc., Optimata Inc., Physiomics Plc, Rhenovia Pharma SAS, Synergix Ltd., and Vascular Sciences.

Commenting on the report, an analyst team said: "The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods.

Enquiry Before Buying @ http://www.marketresearchstore.com/report/global-biosimulation-market-2014-2018-25721#reportPriceDetails

Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer's researchers worldwide."

According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs.

Access Full Industry Report @ http://www.marketresearchstore.com/report/global-biosimulation-market-2014-2018-25721

Further, the report states that one of the major challenges in the market is the high R&D costs associated with the development of biosimulation software. Several biosimulation models offer a virtual patient population to aid the development and testing of drugs, but these models are constructed using a large amount of data, which increases costs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.